In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., ...

Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared Friday. Why it matters: That's good news for Novo Nordisk (whose stock rose 5% ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Small studies link Ozempic and similar drugs to rare but serious eye conditions. However, experts say there's no need to ...

With so many medical options available, deciding which path to take can be overwhelming. While GLP-1 medications like Ozempic and Wegovy hold promise for both weight loss and diabetes management, ...

Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...

Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.